Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) and aTyr Pharma (NASDAQ:ATYR – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.
Institutional & Insider Ownership
15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by insiders. Comparatively, 5.0% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Neuphoria Therapeutics and aTyr Pharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neuphoria Therapeutics | $1.17 million | 10.82 | -$13.45 million | ($6.22) | -0.38 |
| aTyr Pharma | $190,000.00 | 52.41 | -$74.12 million | ($21.83) | -0.18 |
Neuphoria Therapeutics has higher revenue and earnings than aTyr Pharma. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Neuphoria Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.
Profitability
This table compares Neuphoria Therapeutics and aTyr Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neuphoria Therapeutics | N/A | -2.74% | -2.31% |
| aTyr Pharma | N/A | -102.83% | -70.56% |
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Neuphoria Therapeutics and aTyr Pharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neuphoria Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
| aTyr Pharma | 1 | 3 | 1 | 1 | 2.33 |
Neuphoria Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 199.15%. aTyr Pharma has a consensus price target of $5.00, suggesting a potential upside of 28.04%. Given Neuphoria Therapeutics’ higher probable upside, analysts plainly believe Neuphoria Therapeutics is more favorable than aTyr Pharma.
Summary
aTyr Pharma beats Neuphoria Therapeutics on 8 of the 14 factors compared between the two stocks.
About Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions. The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies. Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.
About aTyr Pharma
aTyr Pharma is a clinical-stage biotechnology company focused on developing medicines based on the extracellular biology of tRNA synthetases, a family of proteins involved in cellular processes. The company is headquartered in San Diego, California. Its lead drug candidate, efzofitimod, is an immunomodulator being studied for pulmonary sarcoidosis and other interstitial lung diseases. The candidate is designed to act through neuropilin-2, a receptor involved in immune regulation. aTyr’s research programs draw on its work in tRNA synthetase biology, with the broader goal of developing treatments for inflammatory and fibrotic conditions.
Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
